(C) | 1. | ¥H¤U±Ôz¦óªÌ¤£¥¿½T? |
A. | ¤ß¿é¥X¶q (cardiac output) ¨ú¨M©ó¤ß³t²v (heart rate)¡B«et²ü (preload)¡B«át²ü (afterload) ¤Î¤ß¦Ù¦¬ÁY¤O (contractility) |
B. | ¥D°Ê¯ßÀ£ (¦åÀ£) = ¤ß¿é¥X¶q (cardiac output) x ¨t²Î¦åºÞªý¤O (systemic vascular resistance) + ¥k¤ß©ÐÀ£¡C³q±`¦]¥D°Ê¯ßÀ£ >>¥k¤ß©ÐÀ£¡A¦]¦¹¥k¤ß©ÐÀ£¥i¬Ù²¤¡A ¦Ó¥D°Ê¯ßÀ£ (¦åÀ£) = ¤ß¿é¥X¶qx¨t²Î¦åºÞªý¤O |
C. | ¯ßÀ£ (pulse pressure) ¦bµL°Ê¯ßªý¶ë®É¤Ï¬M¯ß·i±j®z¡C¯ßÀ£¨ú¨M©ó¤ß°Ê®e¿n (stroke volume) »P°Ê¯ß¶¶À³©Ê (arterial compliance)¡C¯ßÀ£»P¤ß°Ê®e¿n§e¥¿¬ÛÃö¡A»P°Ê¯ß¶¶À³©Ê¥ç§e¥¿¬ÛÃö |
D. | ªÍ°Ê¯ßÀ£ = ªÍ¦å¬y¶q* x ªÍ¦åºÞªý¤O + ªÍÀR¯ßÀ£¡C*¦pµL¤ßŦ¥ª¥k¤À¬y (left-to- right or right to-left shunt) ®É¡AªÍ¦å¬y¶q = ¤ß¿é¥X¶q |
E. | ¥H¤W¬Ò¥¿½T |
|
(B) | 2. | ¦b¤U¦CÀVÀR¯ßÀ£¤Wª@±¡ªp¡A¦b¦ó¶µ©|¥i¤p¤ß¨Ï¥Î§Q§¿¾¯¡H |
A. | ¤ß¥]Ån¶ñ¶ë¡]cardiac tamponade¡^¡C |
B. | ºC©Ê³¬Âê©Ê¤ß¥]Ånª¢¡]chronic constrictive pericarditis¡^¡C |
C. | ¤U¾À¤ß¦Ù±ð¶ë¦X¨Ö¥k¤ß«Ç±ð¶ë¡C |
D. | ¤ß°IºÜ¯f¤H¸g¨Ï¥Î§Q§¿¾¯«á©|¦³¸}¸~¡A¦ý¦³°_§¤©ÊÀY·w¤Î§C¦åÀ£¡C |
E. | ¥H¤W¬Ò¾A¦X¨Ï¥Î§Q§¿¾¯
|
|
(C) | 3. | ¤U¦C²ÓM¦óªÌ»P°Ê¯ßµ°ª¬µw¤Æµo¥Í¤Î¶i®i¤§¯f²z¾÷ÂàµLÃö¡H |
A. | ¦åºÞ¤º¥Ö²ÓM (endothelial cell) |
B. | ¥·Æ¦Ù²ÓM (smooth muscle cell) |
C. | B«¬²O¤Ú²y (B lymphocyte) |
D. | ¢â«¬²O¤Ú²y (T lymphocyte) |
E. | ¤j§]¾½²ÓM (macrophage) |
|
(C) | 4. | 48·³¤k©Ê¥D¶D´e¯Ý¡A°¸¦³¯t·w¨Ã¦³¹B°Ê©Ê©I§l§xÃø¡C²z¾ÇÀˬd¯ß¸õ64/min¡A¤ßŦ¤j¤p¥¿±`¡A¦³S4¡A¦b¯Ý°©¥ª½t²Ä¥|¦Ø¶¡¦³Gr IV/VI®g¥X«¬¤ßÁY´ÁÂøµ¡A¦V¤ß¦y¤ÎÀV³¡©ñ´²¡C¦å¦æ¤O¾ÇÀ£¤O¡]mmHg¡^¦p¤U¡G¥k¤ß©Ð¥§¡À£¡G6¡F¥k¤ß«Ç43/8¡FªÍ°Ê¯ß¡G43/16¡]¥§¡À£28¡^¡FªÍ°Ê¯ß·¤À£¡G¥§¡À£22¡F¥ª¤ß«Ç¡G227/33¡F¥D°Ê¯ß139/72¡]¥§¡À£98¡^¡A¯f¤H¤§¤ßŦ¯f¶EÂ_¬°¡G |
A. | ¹¬´Uä¯U¯¶¡C |
B. | ¹¬´U䳬Âꤣ¥þ¡C |
C. | ¥D°Ê¯ßä¯U¯¶¡C |
D. | ¥D°Ê䳬Âꤣ¥þ¡C |
E. | ¤T¦y䳬Âꤣ¥þ¡C |
|
(E) | 5. | ¤U¦C A-D·f°t±Ôz¦óªÌ¤£¥¿½T? |
A. | ¸¡/Iµh, Grey Turner sign - ¸¡°Ê¯ß½F¯}µõ (rupture of abdominal aorta) |
B. | «æ©Ê¯Ýµh, ¥Ö¤U®ð¸~ - ¹¹D¯}µõ (esophageal rupture) |
C. | «æ©Ê¯Ýµh, ©I§l§xÃø, ®ðºÞ°¾¦V (deviation) - ±i¤O©Ê®ð¯Ý (tension pneumothorax) |
D. | «æ©Ê¯Ýµh, ¥ª¤WªÏ¯ß·i®ø¥¢ - °Ê¯ßéÂ÷ (aortic dissection) |
E. | ¥H¤W¬Ò¥¿½T |
|
(D) | 6. | ¤U¦C§Ü¦å¤pªO¾¯¤Î§Ü¾®¦å¾¯¤§§@¥Î¾÷Âà¡A¦óªÌ¬°«D? |
A. | Aspirin-§í¨î cyclooxygenase¡A¦ÓªýÂ_thromboxane¤§²£¥Í |
B. | Ticlopidine¡Bclopidogrel - ADP¨ü®e¾¹ (receptor) ªýÂ_¾¯ |
C. | Abciximab¡Btirofiban - glycoprotein IIb/IIIa¨ü®e¾¹¤§ªýÂ_¾¯¡AªýÂ_¦å¤pªO»Pfibrinogen¤§µ²¦X |
D. | Heparin-ª½±µ¤§§Üthrombin¾¯ (direct anti-thrombin) |
E. | Coumadin (warfarin) - §í¨îºû¥L©RKÄÝ©Ê (Vit. K dependent) ¾®¦å¦]¤lII, VII, IX¤ÎX
|
|
(B) | 7. | ¤U¦CÄòµo©Ê°ª¦åÀ£¡A¦óºØ³Ì®e©ö¶EÂ_? |
A. | Renovascular hypertension |
B. | Coarctation of aorta |
C. | Primary aldosteronism |
D. | Cushing syndrome |
E. | Pheochromocytoma |
|
(B) | 8. | ¦³Ãö©ó«æ©Ê¤ß¦Ù±ð¶ëµo¥Í¤ß«ÇÅÖºûŸ°Ê (Vf, ventricular fibrillation) ªº¤U¦C±Ôz¡A¦óªÌ¬°«D? |
A. | Primary Vf¤j³¡¥÷¦bAMIµo¥Í¤§ÀY12¤p®É |
B. | µ¹¤©lidocaine¹w¨¾Vf¡A¦³§U©ó´î¤ÖAMI¤§¦º¤`²v |
C. | µ¹¤©¹w¨¾©Êlidocaine¡A¦³§U©ó´î¤Öprimary Vf ªºµo¥Í |
D. | Primary Vf ¤£P¼vÅT¤ß¦Ù±ð¶ëªø´Á¦s¬¡²v |
E. | ¦b«æ©Ê¤ß¦Ù±ð¶ë«á´Á¦]pump failure ²£¥Íªº secondary Vf¡A¨ä¹w«á¸û®t |
|
(B) | 9. | Ãö©ó«æ©Ê¤ß¥]Ånª¢ (acute pericarditis) ¤§±Ôz¡A¦óªÌ¬°«D¡H |
A. | ¨å«¬¯Ýµh¡A¦b§l®ð¤Î¥½ö®É¥[¼@ |
B. | 12¾Éµ{¤ß¹q¹Ï§e²{§½³¡©Ê¾Éµ{ST¬q¤Wª@¡]¦p¦bin II, III¤ÎaVf¡^¥B¦³¬ÛÀ³©ÊST¬q¤U° (reciprocal ST depression) |
C. | ¦bÄu©Ê¸`«ß (sinus rhythm) ®É¡A¨å«¬¤§¤ß¥]Ån¼¯À¿µ (friction rub¡^¥Ñ3Ӯɬ۲զ¨ (triple phase)- §Y¦b¤ß«Ç¦¬ÁY¡A¤ß«ÇµÎ±i»P¤ß©Ð¦¬ÁY®É |
D. | ¯f±¡°lÂÜ®ÉÀ³ª`·NÀVÀR¯ßª¬ºA¡A¦pÀR¯ßÀ£¶}©l¤Wª@¡A«hÀ³¦Ò¼{µo¥Í effusive - constrictive pericarditis ©Î¤ß¥]¶ñ¶ë (cardiac tamponade) |
E. | ¥H¤W¬Ò¥¿½T |
|
(E) | 10. | ¦b¤U¦C¦óºØ±¡ªp¤£©y¨Ï¥ÎÂà¤ÆúC§í¨î¾¯ (angiotensin converting enzyme inhibitor) ©Î angiotensin receptor blocker (ARB) ? |
A. | ¨â°¼µÇ°Ê¯ß¯U¯¶ |
B. | ¦³¹ï¦å¬y¦³ÄY«functional or organicªý¤OªÌ
(¦pÄY«¤§¥D°Ê¯ßä¡B¤G¦yä¯U¯¶©ÎªÍ°Ê¯ß°ªÀ£µ¥)
|
C. | ¤w¦³©ÎÃhºÃ¦³«et²ü (preload) ¥i¯à¤£¨¬±¡ªpªÌ (¦p¾É¦]©ó¹Ã¦R¡B¸¡Âm¡B¥X¦å¤Î¹L·í¨Ï¥ÎÀR¯ßÂX±i¾¯©Î/¤Î§Q§¿¾¯µ¥) |
D. | ¦³°_§¤©Ê§C¦åÀ£ªÌ |
E. | ¥H¤W±¡ªp¬Ò¤£©y¨Ï¥Î¦¹ÃþÃĪ« |
|
(E) | 11. | ¦³Ãö¤ßŦÂH²G½F (myxoma) (1) -(5) ±Ôz¤§²Õ¦X¡A¦óªÌ¬°¥¿½T ?1. ÂH²G½F¬°³Ì±`¨£¤§ìµo©Ê¤ßŦ´c©Ê¸~½F2. ¥i¯à¥HªÍÆ{¦å¡B°Ê¯ß®ê¶ë¡Bµo¿N¡B©ü³Ö¡BÖ`¦ºµ¥ªí²{3. ¤ßŦť¶E¡AÂøµ¥i¯à¦]Åé¦ì§ïÅܦӦ³©ÒÅܤÆ4. ¤ßŦ¶Wµªi¬°³Ì¦nªº¶EÂ_¤u¨ã5. ¶EÂ_«á¤@¯ë¤£§@¤ß¾ÉºÞÀˬd¡AÀ³§Y®É¶}¤M |
A. | 1 + 3 + 4 |
B. | 1 + 2 + 4 + 5 |
C. | 3 + 4 + 5 |
D. | 1 + 2 + 3 + 4 |
E. | 2 + 3 + 4 + 5 |
|
(D) | 12. | ¦³Ãö1 - 5 ±Ôz¤§²Õ¦X¡A¦óªÌ¬°¥¿½T? 1. ¤ò¦a¶Àdigoxin¡A¤A«¬¥æ·P¯«¸gªýÂ_¾¯¡A¶tÂ÷¤lªýÂ_¾¯¤§verapamil©Îdiltiazem¹ï¤ß©ÐŸ°Ê¦³±±³t§@¥Î (rate control)¡A¥i¦³®Ä±±¨î§Ö³t¤§¤ß«Ç³t²v 2. ¦b¥Òª¬¸¢¥\¯à¤®¶i¯f¤H±±¨î¤ß«Ç³t²v¤§º¿ïÃĪ«¬°¤A«¬¥æ·P¯«¸gªýÂ_¾¯propranolol 3. Amiodarone¥Î©óªvÀø¤ß©ÐŸ°Ê¥Dn¬°±±«ß§@¥Î (rhythm control) -- ±N¤ß©ÐŸ°ÊÁB¥¿¬°Äu©Ð²v (sinus rhythm) ©Î¹w¨¾¤ß©ÐŸ°Ê¦Aµo¥Í¡C¨Ï¥Îamiodarone¦³¥i¯à¤zÂZ¥Òª¬¸¢¥\¯àÀˬd 4. ¨Ï¥Îdigoxin±±¨î¤ß«Ç³t²v¡A¤£¥²ºÊ±±¦å¤¤¿@«× 5. Digoxin¦X¥Îamiodarone¡Bverapamil©Îaldactone¦³¥i¯àµo¥ÍÃĪ«¥æ¤¬§@¥Î (drug interaction)¡A¾ÉPdigoxin¦å¤¤¿@«×¼W¥[ |
A. | 1 + 3 + 4 |
B. | 1 + 2 + 5 |
C. | 3 + 4 + 5 |
D. | 1 + 2 + 3 + 5 |
E. | 1 - 5 ¬Ò¥¿½T |
|
(A) | 13. | ¹ïÄY«¥D°Ê¯ßä¯U¯¶»Pªý¶ë©ÊªÎ«p©Ê¤ß¦Ù¯f¨âªÌ1 - 5 ±Ôz¤§²Õ¦X¡A¦óªÌ¬°¥¿½T?1. ¨âªÌ¦³¬Û¦ü¤§Á{§Éªí²{¥]¬A©I§l§xÃø¡B¯U¤ß¯g¡B©ü³Ö¤ÎÖ`¦º2. ¨âªÌÀV°Ê¯ß·i°ÊÅã¥Ü©µ¿ð¤W³» (slow upstroke)3. ¨âªÌ¤ß¹q¹ÏÅã¥Ü¥ª¤ß«ÇªÎ¤j4. ¦b«áªÌ¦¬ÁY´ÁÂøµ¦b§@Valsalva°Ê§@®É¤Î¯¸¥ß®ÉÅܤj¡AÃÛ¤U®ÉÅܤp5. ¤ß°IºÜ®É¨âªÌ¬Ò¥i¨Ï¥ÎdigoxinªvÀø |
A. | 1 + 3 + 4 |
B. | 1 + 2 + 5 |
C. | 3 + 4 + 5 |
D. | 1 + 2 + 3 |
E. | 1 - 5 ¬Ò¥¿½T |
|
(A) | 14. | ´NÀI¦V¦]¯À(Risk factor)¤§P¯f±j«×¦Ó¨¥,¤U¦C¦ó²Õ¸sªº°Oz¬O¥¿½Tªº ;1.©â·Ï¹ï«a¤ß¯f(coronary heart disease) ¤Î¥½±é¦åºÞ¯f(Peripheral artery disease)¤§P¯f±j«×»·¤ñ¸£¤¤·¬°«2.°ª¦åÀ£·|««×¼vÂQ¸£¤¤·¤§µo§@3.¦å²M¤¤°ªLDL-C¤Î/©Î§CHDL-C¦h¨£©ó«a¤ß¯f4.¿}§¿¯f¹ï¤¤·ªº¦MÀI©Ê»·¤j©ó«a¤ß¯f5.¦å²MC-reactive protein¤§¤Wª@¹ï¤¤·ªº¦MÀI©Ê»·¤j©ó«a¤ß¯f |
A. | 1+2+3 |
B. | 4+5 |
C. | 1+3+5 |
D. | 2+4 |
E. | 1+4+5 |
|
(C) | 15. | ¯f¤H¬O43·³¥Í·N¤H,¸g±`¥X°ê¸g°Ó,©ó¤¤ë¤Q¤»¤é¦]¦³¶i®i©Ê©I§l§xÃø¤D¦Ü«æ¶E¨DÂå,¯f¤H©ó¤¤ë¤T¤é®È¦æ¤é¥»®É¬ð¦³©¿§N©¿¼ö,¦ñ¦³°®«y©I§l§xÃø¤Î¯Ý´e,¥B·í®É¦Û¶q¦åÀ£¥u¦³90/60
mmHg,¨ä«á¯gª¬µy¸Ñ,¤D¦^°ê¥ð¾i,¦ý¦b¤¤ë¤Q¥|¤é¹B¾±©Ê©I§l§xÃø³vº¥Âà¼@.²z¾Ç:¦åÀ£95/75
mmHg;¤ß¸õ78/¤À¡A³W«h«ß¸õ;ÀVÀR¯ß¥¿±`,¦ý¤ßŦÅãµÛÂX¤j,S1¤ÎS2³£Âà®z;³£µL¤ßÂøµ,¨ä¥L²z¾Ç©Ò¨£©|ºÙ¥¿±`.¯f¤H¦³°ª¦åÀ£¤Î°ª¯×¦å¤Î¨C¤Ñ©â·Ï1.5¥]¦³¤T¤Q¦~¤§¤[,¥B¦b1.5¦~«e´¿¦³µu°}©Ê¸£¯Ê¦åµo§@.,¥Í¤ÆÀˬd:¥u¦³GOT
50u/L;GPT 25u/L;Troponin I(ng/ml), CK,(U/L)CK-MB(U/L):¤¤ë¤Q¤»¤é -
5.65,246,17.1;¤¤ë¤Q¤C¤é- 3.74,190,10.1;¯Ý³¡X¥ú¤Î¤ß¹q¹Ï ¦p¥Ü,½Ð°Ý¤U¦C¦óªÌ¬O³Ì¦³¥i¯àªº¶EÂ_? |
A. | «DST¤Wª@«æ©Ê¤ß¦Ù±ð¶ë¯g |
B. | ¤ßµ±µh |
C. | ¤ß¦Ùª¢¦X¨Ö¤ß¦Ù¯fÅÜ |
D. | °ª¦åÀ£©Ê¤ßŦ¯f |
E. | ªÍ°Ê¯ß¦å®ê¯g |
|
(D) | 16. | ¯f¤H¬O¦ì31·³·~°È±À¾Pû¡A´¿¬OÄx²y°ê¤â¡A³Ìªñ¤@©P®É¦³¹B°Ê©Ê©I§l§xÃø¡A¦P®É¦ñ¦³Âù¸}¤ô¸~¡A¦]¦Ó¦í°|¶EÀø¡C¯f¤H¥|¦~«e´N´¿¦³´X¦¸ª±²y«á¦³«y¦å·ð¤Î³vº¥¹B°Ê@¨ü¤£¨¬¡A±q¦¹°±¤î³oÓ¹B°Ê¶Ý¦n¡C¯f¤H´¿¦³¨DÂåªvÀø¡A¨Ï¥ÎCordarone,
Furosemide ¤ÎSpirolactone¤§°O¿ý¡C²z¾ÇÀˬd¡G¦åÀ£98/64
mmHg¡F¤ß¸õ,60/min¡A³W«h«ß¸õ¡AÀVÀR¯ß«ã±i¡A¦³©úÅãvªi¡A¯Ý³¡¦³¿Bµ¡A¥ª¥k¤ß«ÇÅãµMÂX¤j¡A¦b¤ß¦y¦³Gr III/VI Pansystolic
blowing murmurª½¶Ç¥ªµÅºÛ¡A¦P®É¦³S3¥i»D¡AP2¤]µy¥[±j,¨ÃµL¨xµÊ¸~¤j¤Î¸¡¤ô¤§¥X²{,°ßÂù¸}¤ô¸~¡C¤ß¹q¹Ï¡B¯Ý³¡X¥ú¡B¶Wµªi¤ß¹Ï¤Î¦å¦æ¤O¾ÇÀˬd¡A¦p¹Ï©Ò¥Ü¡G¥»¯f¤H³Ì¥i¯àªºÁ{§É¶EÂ_¬O |
A. | °ª¦åÀ£©Ê¤ßŦ¯f
|
B. | ¯Ê¦å©Ê¤ßŦ¯f |
C. | ªÍ©Ê¤ß |
D. | ÂX±i©Ê¤ß¦Ù¯f |
E. | ªÎ«p©Ê¤ß¦Ù¯f |
|
(B) | 17. | 75·³¤k©Ê¥D¶D³Ìªñ¥b¦~³vº¥¥[«ªº¹B°Ê©Ê©I§l§xÃø¤Î´¿¦³¼Æ¦¸©ü³Ö,¯f¤H¤_10¦~«e¦]¹¬´Uä¯U¯¶±µ¨ü¾÷±ñ©Ê佤¸m´«³N,¨ä«á¯f±¡¥¶¶,¤£·Nªñ¥b¦~¶}©l¹B°Ê@¨ü¤£¨¬,®É±`«_¦½¶¡¦³µu°}©ü³Ö,²z¾ÇÀˬd:¦åÀ£,103/60 mmHg;¤ß¸õ,80/min ³W«ß,ÀVÀR¯ß¯B±i,¦³Vªi,¤ßŦÂù°¼ÂX¤j,¥iºN¨ì¥ª¥k¤ß«Ç¬ð¸õ(Heave),¦b¥D°Ê¯ß°Ï¦³GrIII-IV/VI Systolic ejection murmur¦P®É¶ÇÁn¦ÜÀV°Ê¯ß,A2´îÁn,¦b¤ß¦y°Ï¥iÅ¥¨ì¹¬´Uä¶}¦XºVÀ»Án(Opening & closing click),¦b¥k°¼¯Ý°©¤U½t³B¦³§l®ð¥[±jªºGr II/IV Systolic blowingmurmur,¦³»´«×¸¡¤ô¤ÎÂù¸}¯B¸~.¸g¶Wµªi¤ß¹Ï½T©w¥D°Ê¯ßä¯U¯¶,¬ï¶V佤À£¤O®t¦³69 mmHg,¥D°Ê¯ßä¶}¤f±¿n0.9 cm2,¤H¤u¹¬´Uä¥\¯à¥¿±`.¥ª¤ß«ÇµÎ±i/¦¬ÁYª½®|50/33;¥ª¤ß©Ð,43 mm;¥ª¤ß«Ç¾À,9 mm¡C¾ÉºÞÀˬdµý¹ê AS + AR + TR¤Î¥¿±`¤H¤u¹¬´Uä.¥»¯f¤H¨ÌÕu²{¦æAHA/ACCªvÀø«ü¤ÞÀ³¦æªº³B¸m,¤U¦C¦óªÌ¬O¥¿½Tªº? |
A. | ¦Ñ¦~°ªÄÖ,¤£¾A¥~¬ì¤â³N |
B. | ¦³¯gª¬ªº¥D°Ê¯ßä¯U¯¶À³³w¦æ¥~¬ìä¯ß¸m´«¤â³N |
C. | ¥»¯f¨Ò±o¥H¾ÉºÞ®ð²yÂX±i³N§@¥D°Ê¯ßä¾ã§Î¤â³N |
D. | ¥»¯f¨Ò¥Hdigoxin ¤Î§Q§¿¾¯ªvÀø§Y¥i |
E. | «O¦uªº´_°·ªvÀø³Ì¦w¥þ |
|
(E) | 18. | ¦b¹êµýÂå¾Ç±j«×Class 1¤ÎLevel A ªº½×ÂI,¹ï«DSTªi¬q¤Wª@¤ß¦Ù±ð¶ë(Non ST elevation myocardial infarction,NSTEMI) ¯f¤H¤§¤U¦C¦óºØª¬ªp,¥i¤£¥²³w¦æ¦´Á¿n·¥³B¸m(Early invasive management). |
A. | ¦b¦í°|ªvÀø¤¤¤´¦³«ùÄò©Ê¤ßµ±¯k |
B. | ¦åÀ£ 88/76 mmHg |
C. | «ùÄò©Ê¤ß«Ç©Ê§Ö¸õ(Sustain ventricular tachycardia) |
D. | ·s²{STªi¬q¤U¨H(ST depression) |
E. | ¦å²MTroponin I, 0.5 ng/ml |
|
(A) | 19. | ¤U¦C¦³Ãö«DST¤Wª@«æ©Ê«a¤ß¯gÔ¸s(Non ST elevation ACS)ªºÁ{§É°Oz,¦óªÌ¬O¤£¥¿½Tªº |
A. | ¦´Á³qºZ¦åºÞ(Early revascularization)¥i§ïµ½«DST¤Wª@«æ©Ê¤ß¦Ù±ð¶ë(NSTEMI) |
B. | ¥»¯gÔ¸s¦h¨£©ó¦Ñ¤H,¦³¤ß¦Ù±ð¶ë¯f¥vªÌ,¦³¦hºØ¤ß¦åºÞ¯f¦MÀI¦]¯ÀªÌ |
C. | ¤T¤À¤§¤G¦¹Ãþ¯f¤Hªº«aª¬°Ê¯ß¯U¯¶¤Ö©ó50%,¨ä¦åºÞ³y¼v¦h§e¨£«D¹ïºÙ©Ê,ªøªu©Ê¤Î°~®kÅs¦±¯U¯¶ |
D. | Enoxaparin¤ñ¶Ç²ÎªºHeparin¹ï¥»¯g³Ì¨ãÀø®Ä |
E. | «DST¤Wª@«æ©Ê¤ß¦Ù±ð¶ë¯g¯f¤H¤§¦í°|¦º¤`²v¤ñST¤Wª@«æ©Ê¤ß¦Ù±ð¶ë¯g¯f¤H¬°§C,¦ý´Nªø´Áªº¦º¤`²v¦Ó¨¥,¨âªÌ¬O¤£¤À°a¸þªº |
|
(C) | 20. | ¦³Ãö¤ßŦ°IºÜªvÀøªº¹êµýÂå¾Ç¥]¬A¤U¦C¦U¶µ:1.ACE inhibitors¹ïµL¯gª¬©Î««×¯gª¬ªº¯f¤H³£À³¸Ó¨Ï¥Î¡B°£«D¦³Ãø§Ô«y¹Â¡BµÇ¥\¯à°h®i©Î§C¦åÀ£¤§µo¥Í2.Beta-blockers¤£À³¦b¤£Ã©w«¬ªº¤ß°IºÜ¡B§C¦åÀ£¤Î®e¿n¹L±i(Volume overload)ªº¯f¤H¨Ï¥Î3.Digoxin¤£¯à°§C¦º¤`²v¦ý¥B¦³¤¤¬rªº¦MÀI,¤£À³¨Ï¥Î4.Cardiac resynchronization therapy CRT»ù¿ú°ª¡A¦ý¹ï©Ò¦³¤ßŦ°IºÜªº¯f¤H¦³ÅãµÛÀø®Ä?5¤ßŦ²¾´Ó¬O¥Ø¼ÐªvÀø(Destination therapy)¤U¦C¦óªÌ¬O¥¿½Tªº½×µý? |
A. | 1 + 2 + 3
|
B. | 1 + 2 + 4 |
C. | 1 + 2 + 5 |
D. | 2 + 3 + 4 |
E. | 2 + 3 + 5 |
|
(E) | 21. | ¤@¦ì22·³¹B°Êªø¶]°ª¤â¡A¤é±`¨ÃµL¥ô¦ó²§±`¯gª¬¡A¥u¦³ÅéÀˮɵo²{¤ß¸õ¤ÓºC¡C24¤p®É¤ß¹q¹Ï°O¿ýÅã¥Ü·¥«×Äu©Ê¤ß¸õ½wºC¤¶©ó35 -45/min¡A¹B°Ê¤ß¹q¹Ï¨Ã¥¼¦³¤ß¦Ù¯Ê®ñÅܤơC½Ð°Ý±zªº³B¸m¨BÆJ¬O: |
A. | ¬I¦æ¤ßŦ¶WµªiÀˬd
|
B. | ¬I¦æ¹q®ð¥Í²z¾ÇÀˬd |
C. | ¸Ë¸m¤H¤u¤ß«ß½Õ¸`¾¹ |
D. | ¬I¦æ¹B°Ê¤ß¦ÙThallium201Äéª`Åã¼v |
E. | ©w´Á°l°lÂÜÀˬd |
|
(C) | 22. | ¦³Ãö¤ßªÍ´_µd³N(CPR)ªº·sªñ¹ê¯gÂå¾Ç½×ÂI¡A¤U¦C¦óªÌ¬O¿ù»~¡H |
A. | epinephrine°ª¾¯¶q(5-14mg)ªº¤ñ¶Ç²Î¾¯¶q(1mg)¦³§U¤ßŦ´`Àô¤§´_ì¡A¦ýµL¯q©ó¸£¥\¯à¦^´_¤Î¦º¤`²v¤§§ïµ½ |
B. | ÀR¯ßª`®gsodium bicarbonate¤£¯à§ïµ½¤ß¦Ùªº¥NÁ©ʻĤ¤¬r¡A¤Îventricular f ibrillation ªº²£¥Í |
C. | ¾¨¦¹ê¬I¤f¹ï¤fªº¤H¤u©I§l¤ñ¤ß¥~«ö¼¯§ó¦³±Ï¬¡¯f¤Hªº¾÷·| |
D. | ·s¦¡ªº Active compression decompression CPR¥i§ïµ½«aª¬°Ê¯ßÄéª`À£¤O¡A¦ý¤´µL§U©ó¦º¤`²v¤§§ïµ½ |
E. | ¾¨³t±Ò¥Î¿n·¥Åé¥~¥hŸªvÀø(AED¡^¦³§U©óCPRªº¦¨¥\ |
|